Genomewide Association Studies in Pharmacogenomics

Citations Over TimeTop 1% of 2021 papers

Abstract

The increasing availability of genotype data linked with information about drug-response phenotypes has enabled genomewide association studies (GWAS) that uncover genetic determinants of drug response. GWAS have discovered associations between genetic variants and both drug efficacy and adverse drug reactions. Despite these successes, the design of GWAS in pharmacogenomics (PGx) faces unique challenges. In this review, we analyze the last decade of GWAS in PGx. We review trends in publications over time, including the drugs and drug classes studied and the clinical phenotypes used. Several data sharing consortia have contributed substantially to the PGx GWAS literature. We anticipate increased focus on biobanks and highlight phenotypes that would best enable future PGx discoveries.

Related Papers

• → Advances in Pharmacogenetics and Pharmacogenomics(2000)70 cited
• → Pharmacogenetics and pharmacogenomics as tools in cancer therapy(2016)32 cited
• → Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response(2015)1 cited
• [Pharmacogenomics: way to individual therapy].(2005)
• → Pharmacogenetics and Genetic Factors in Drug Dose-Response Relationships(2023)